Vanguard Real Estate Index Fund ETF News
Flood Costs in Several States' Commercial Real Estate Set to Soar
Flood damage from climate change could cost the commercial real estate industry $16.9 billion a year by 2052, the report says.
GEO Shares Fall as it Drops REIT Structure and Turns C Corp.
The switch to C corporation from REIT 'is expected to give GEO flexibility to allocate free cash flow toward reducing net recourse debt,' it said.
How to Invest in Real Estate: Buying vs. Not Buying Property
Investing in real estate can mean dozens of different things. Here's what to know about how to invest while buying property and how to invest without buying property.
Realty Income Is a 'Buy the Dips' Stock Post Earnings
This big REIT is on a trajectory for higher ground. Charts show how to trade it.
Investing for Retirement? Think Income Producing REITs
REITs haven't gotten much attention in recent years, as real estate focused stocks have underperformed a roaring broader market. But with low interest rates and rising inflation risks, REITs deserve a second look.
3 Stocks That Could Help You Survive an Inflation Spike
Higher inflation has investors spooked. Here's a look at three trades that could protect against inflationary downside in 2018.
U.S. Housing Market Is on Fire Again and These 3 Stocks Are Loving It
The U.S. housing market is, metaphorically, a house-on-fire. That spells opportunity for sector investors.
This REIT Profits From Trump's Immigration Crackdown
We've found a high-yielding real estate investment trust that's a play on the president's program to stem illegal immigration.
Why this one investment pro loves Exxon, AT&T and REITs in 2017
Oil, telecoms and REITs may stand to benefit in 2017, as investors still need income from dividends. The changing political landscape may help too.
Trump's Potential Return to Twitter Under Musk Hits Digital World
Digital World Acquisition, a company attempting to merge with former President Donald Trump's media group Truth Social, faces a new challenge.
Bluebird Bio's 2nd Approval Doesn't Guarantee Survival
Investors hoping for a revival at the struggling biotech might want to temper their expectations.